Please login to the form below

AC Immune

This page shows the latest AC Immune news and features for those working in and with pharma, biotech and healthcare.

FDA grants fast track designation to AC Immune’s Alzheimer’s disease vaccine

The US Food and Drug Administration (FDA) has granted fast track designation to AC Immune SA’s investigational anti-amyloid beta immunotherapy vaccine for Alzheimer’s disease. ... Dr Andrea Pfeifer, chief executive officer of AC Immune SA, said:

Latest news

Mixed results for AC Immune's promising Alzheimer’s antibody

Shares in AC Immune rose more than 75% on the news that semorinemab met one of two study endpoints. ... AC Immune shares rose more than 75% on the announcement, marking a “surprising” turnaround for the programme for Jefferies analyst Lucy Codrington.
Germany’s Vivoryon raises €43m for Alzheimer’s drug trial

The announcement of aducanumab’s demise as well as the failure of AC Immune and Roche’s crenezumab and other amyloid-targeting agents including Biogen/Eisai’s elenbecestat and Amgen/Novartis’
Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms

The failure of two other beta amyloid targeting agents this year – AC Immune and Roche’s crenezumab and Eisai and Biogen’s aducanumab has lead many to declare the need to ... Funding is now pouring into a number of entirely novel modalities,
Another amyloid bust as Roche pulls crenezumab trials

The setback for the AC Immune-partnered drug is yet another blow to proponents of the amyloid hypothesis for AD – which holds that interrupting the formation of amyloid plaques in the ... Roche and AC Immune’s drug failed to move the needle on
Lilly partners with AC Immune on tau drug for Alzheimer’s

CHF 80m ($81m) upfront to license a tau-targeting candidate from Switzerland’s AC Immune. ... The deal for the preclinical stage ACI-3024 drug also includes another $50m in a note that is convertible to AC Immune stock, CHF 60m in near-term milestones,

More from news
Approximately 3 fully matching, plus 16 partially matching documents found.

Latest Intelligence

A roadmap to the successful treatment of Alzheimer’s disease

We cannot – and should not – look away. Professor Dr Andrea Pfeifer is co-founder and CEO of AC Immune, a biotech headquartered in Lausanne, Switzerland, with one of the broadest clinical ... Professor Dr Andrea Pfeifer is co-founder and CEO of AC
Where next in Alzheimer’s disease R&D?

Rising interest in tau is reflected in a series of deals involving AC Immune. ... AC Immune and its partners are far from the only drug developers to target tau.
Holding on to hope for Alzheimer’s advances

There was also some enthusiasm in San Diego for Roche and AC Immune’s crenezumab.
Deal Watch table for January 2015

Exclusive licence. 522. AC Immune/ Janssen. To develop and commercialise therapeutic anti-Tau vaccines [ACI35, P1] for the treatment of Alzheimer's disease.
Pharma deals during January 2015

A further $509m was allocated to the exclusive worldwide licence with AC Immune for ACI-35 anti-Tau vaccines in Alzheimer's disease (upfront not disclosed).